measurement of bactericidal antibody as an indicator of vaccine effectiveness l.
Skip this Video
Loading SlideShow in 5 Seconds..
Measurement of Bactericidal Antibody as an Indicator of Vaccine Effectiveness PowerPoint Presentation
Download Presentation
Measurement of Bactericidal Antibody as an Indicator of Vaccine Effectiveness

Loading in 2 Seconds...

play fullscreen
1 / 18

Measurement of Bactericidal Antibody as an Indicator of Vaccine Effectiveness - PowerPoint PPT Presentation

Download Presentation
Measurement of Bactericidal Antibody as an Indicator of Vaccine Effectiveness
An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Measurement of Bactericidal Antibody as an Indicator of Vaccine Effectiveness Wendell D. Zollinger, Ph.D. April 6, 2011

  2. The importance of bactericidal antibodies in human immunity to meningococcal disease Available evidence (to be discussed by others) supports the use of the hSBA as a valid serologic marker of protective immunity A serologic marker of protection refers to a marker that is a measure of the biological function that is associated with immunity and can substitute for a clinical end point such as efficacy.

  3. Bactericidal Assay -- Complement Mediated Lysisby Specific Antibody Assay Composition • Buffer/Diluent • Serial 2-fold dilutions of test serum • Log phase bacteria • Complement (serum or plasma without intrinsic bactericidal activity) Antibody requirements • Correct isotype: IgG3>IgG1>IgG2, IgM • High avidity Antigen requirements • Adequate surface exposure to bind antibody and fix C’ • Relatively high surface density (C’ fixation requires two IgG molecules bound close together)

  4. Protective Level of Bactericidal Antibodies • Work of Goldschneider, et al. was done using a titer of 1:4 with intrinsic human complement as a level that correlated with protection • Some have suggested that 1:8 would be a safer level to use • End point taken as the highest serum dilution giving ≥50% killing • Several studies have explored the question

  5. Correlation of hSBAtiters with efficacy using Norwegian group B OMV Vaccine

  6. Efficacy predicted on the basis of a population based marker of immunityA titer of ≥ 1:8 in the BR-SBA corresponded to the observed efficacy in UK. RC-SBA measured 1 month following vaccination with the MCC vaccine(Andrews N, et al. ClinDiagn Lab Immunol 2003;10:780-6)

  7. Standardization of the SBAPrincipal Variables Choice and management of test strains Complement source Assay method used

  8. Assay results can vary considerably depending on the parameters of the assay • The assay method used in different laboratories may vary with respect to: • Growth and handling of the test strain • Source and concentration of complement • Growth media and diluent composition • Incubation time and conditions • Method of determination of cell viability • Definition of end point titer • Assay standardization is needed if lab to lab comparisons are to be meaningful

  9. Range of Different Conditions Used in Different Laboratories

  10. Importance of the Complement Source Used in the Bactericidal Assay • The studies of Goldschneider, et al. were done using human complement • SBA with human complement is the best serologic marker of protection as it is consistent with the in vivo biological mechanism of protection. • Baby rabbit complement may be more convenient and easier to standardize, but it gives significantly different results: • Generally much higher titers (but differences are more complex than that) • Rabbit factor H not bound by meningococcal fHbp • RC appears to function with lower avidity antibodies (human antibodies to group B polysaccharide, which are IgM and low avidity, are bactericidal with rabbit complement but not with human complement.) • Efforts have been made to correlateBR-SBA with hSBA but results in a population based marker of protection and is not reliable when applied to individual protection.

  11. Complement Source (Cont.) • Donor specific differences in human complement can be averaged by creating pools from multiple donors. • Complement activity should be measured and verified to be within an acceptable range before use

  12. Target Strain Considerations • Target strains vary considerably in susceptibility to killing by the same sera (differences in amount of capsule, fHbp, LOS , etc.) • The “same strain” present in different laboratories may not be identical due to phase variation and different handling of the strain • Test strains should under go thorough initial characterization and multiple samples of each strain stored as master and working cell banks. • Some important antigens to characterize and monitor are: capsule, LOS, Opc, factor H binding protein, and key vaccine antigens

  13. Effect of LOS alpha-chain length on group B strain sensitivity to bactericidal antibodyMoran, et al. Infect. Immun. 62:5290-5, 1994

  14. Target Strain Considerations (cont.) • Use many cells to inoculate growth for use in the assay rather than a single colony • For group B vaccines a panel of strains is required to demonstrate the breadth of protection across group B strains. Choice of the strains for the panel may need to be vaccine specific. • For capsular polysaccharide vaccines only a single strain is needed for each serogroup. The sensitivity of the chosen test strain to killing by the bactericidal mechanism should be representative of the majority of case isolates.

  15. Impact of Two Assay Parameters: hSBAtiter step differences by reaction mixture motion and population type Borrow, et al. Clin. Diagn. Lab. Immunol. 12:970-976, 2005 *Raking results – Stationary results **mixed population – single colony results

  16. Assay Standardization Progress(Mostly focused on Group B) • International Meeting : Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Borrow et al. Vaccine. 24:5093-107, 2006. • Multi-laboratory study by Borrow, et al. (ClinDiag Lab Immunol 12:970-976, 2005). Showed good inter-laboratory reproducibility if strain, reagents, and method were controlled. Looked at the effect of different variables. • New Zealand assay validation: Martin D, McCallum L, Glennie A, Ruijne N, Blatchford P, O'Hallahan J, Oster P. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine. 2005 Mar 18;23(17-18):2218-21.

  17. Interlaboratory Comparison with Assay Parameters Controlled to Different Degrees Borrow, et al. Clin. Diagn. Lab. Immunol. 12:970-976, 2005

  18. Summary and Conclusions Human complement-mediated bactericidal activity is thebest biological marker of protectionand most relevant to individual protection and assessment of vaccine immunogenicity. The SBA measures functional antibodies that have been shown to be important for protection from systemic disease. Standardized assay needed with important variables controlled Choice and management of the target strain a critical factor in SBA Good agreement can be obtained between laboratories if the assay is sufficiently standardized